Personalized Mean Arterial Pressure Management on Renal Function During Septic Shock

Acute Kidney Injury Clinical Trial

— DORESEP  

Official title:

Personalized Haemodynamic Management of Septic Shock: Influence of Mean Arterial Pressure Level on Renal Function: Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01473498
• Other study ID #: P091103
• Status: Completed
• Phase: N/A
• Start date: January 2013
• Est. completion date: November 2015

Study information

• Verified date: January 2020
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Sepsis is the most severe complication of infections. Sepsis-associated Acute kidney injury (AKI) is commonly encountered in critically ill patients and independently predicts poor outcome. Unfortunately, no drug or management strategy was able to reduce incidence of AKI. To adapt the level of mean arterial pressure according to local renal hemodynamic evaluated by renal Doppler could lead to a better renal perfusion, and then less AKI.

Description:

Acute Kidney Injury (AKI) is a frequent and serious complication of sepsis. Renal ischemia plays a major role in the pathophysiology of sepsis-associated AKI. There is currently no treatment to prevent or to treat AKI. It has been shown that a resistivity index (RI) greater than 0.74 of patients with septic shock could predict the occurrence of renal failure, and that increase mean arterial pressure (MAP) with norepinephrine could decrease RI. Hence, we propose to compare the frequency and the severity of the sepsis-associated AKI according to the early hemodynamic management of septic shock. Patients will be randomized in a classic group (MAP 65 mmHg) and an interventional group (MAP 85 mmHg). We can thus determine whether the level of MAP influences renal function, and whether this influence of MAP is dependent of renal perfusion assessed by renal Doppler.

Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.

Primary endpoint:

-Presence and severity of sepsis-associated AKI at day 7.

Secondary endpoints:

• Acute renal failure measured by Classification AKI at day 28.

• Acute renal failure as measured by the RIFLE classification in the fourth to seventh day and 28th day.

• Use of renal replacement therapy during hospitalization in intensive care unit

• Mortality at day 28 Duration of study: Recruitment: 10 months, the patient monitoring:

28 days ± 3 days, total test duration: 11 months

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: November 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any patient with septic shock may be included in the next 6 to 16h

• Age > 18 years old and <= 80 years

Exclusion Criteria:

• Chronic renal failure (Baseline serum creatinine > 120 mmol/L)

• Chronic cardiac failure (Left ventricle ejection fraction < 40%)

• Pregnancy

• Urinary Tract Infection

• Patients with a left ventricular dysfunction ( ventricular ejection fraction <40%)

Related Conditions & MeSH terms

• Acute Kidney Injury
• Septic Shock
• Shock
• Shock, Septic

Intervention

Other:
• Haemodynamic management
Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups. In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients.
• Haemodynamic management
Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups. In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg.

Locations

Country	Name	City	State
France	Reanimation Chirurgicale - Hôpital Kremlin Bicêtre	Kremlin Bicêtre

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acute kidney injury according to RIFLE score		at 7 days
Secondary	Need for renal replacement therapy	including metabolic indications (Azotemia Serum urea = 36mmol/L (100 mg/dL) ; Uremic complications : encephalopathy, pericarditis, bleeding ; Hyperkalemia K+ = 6 mmol/L and/or electrocardiogram abnormalities ; Hypermagnesemia =4 mmol/L and/or anuria/absent deep tendon reflexes ; Acidosis Serum pH = 7.15), Oligo-anuria Urine output <200mL/12 h or anuria, Fluid overload like Diuretic-resistant organ edema in the presence of acute kidney injury.	during hospitalization
Secondary	All cause mortality	All Cause mortality at 28 days, including refractory shock, refractory hypoxia, multiple organ failure, decisions to forgo life-sustaining therapies (DFLSTs)	at 28 days